UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Current treatment options in oncology, ISSN 1527-2729, 2/2018, Volume 19, Issue 2, pp. 1 - 14
Medicine & Public Health | JAK2 V617F | Oncology | Polycythemia vera | Diagnosis | Management | Natural history | Life Sciences & Biomedicine | Science & Technology | Leukocytosis - complications | Splenomegaly - complications | Thrombocytosis - complications | Humans | Hematocrit | Janus Kinase 2 - genetics | Thromboembolism - complications | Polycythemia Vera - genetics | Polycythemia - complications | Polycythemia Vera - etiology | Polycythemia Vera - physiopathology | Care and treatment | Chemotherapy | Usage | Polycythemia | Leukemia | Hemoglobin | Thromboembolism | Health aspects | Cancer | Index Medicus
Journal Article
2.
Full Text
Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia
Nature medicine, ISSN 1078-8956, 2013, Volume 19, Issue 4, pp. 437 - 445
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Macrophages - physiology | Stress, Physiological - physiology | Reticulocytes - physiology | Clodronic Acid - pharmacology | Humans | Mice, Inbred C57BL | Hematocrit | beta-Thalassemia - physiopathology | Erythropoiesis - drug effects | Male | Erythropoiesis - physiology | Animals | Female | Macrophages - drug effects | Mice | Erythrocyte Count | Hemoglobins - analysis | Polycythemia Vera - physiopathology | Disease Models, Animal | Erythropoiesis | Regulators | Animal models | Erythropoietin | Anemia | Erythrocytes | Thalassemia | Polycythemia vera | Macrophages | Enucleation | Organic chemistry | Erythroblasts | Polycythemia | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 426 - 435
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pyrazoles - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Spleen - drug effects | Thrombocytopenia - chemically induced | Remission Induction | Blood Cell Count | Janus Kinases - antagonists & inhibitors | Organ Size - drug effects | Hydroxyurea - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Hydroxyurea - therapeutic use | Polycythemia Vera - drug therapy | Aged | Spleen - pathology | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Spleen | Thrombocytopenia | Splenomegaly | Herpes zoster | Inhibitor drugs | Hematocrit | Polycythemia vera | Hydroxyurea | Thrombosis | Patients | Side effects | Polycythemia | Janus kinase | Remission | Blood diseases | Thromboembolism | Drug therapy | Drug dosages | Nuclear magnetic resonance--NMR | Phlebotomy | Restless legs syndrome | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Polycythemias | General aspects | Diseases of red blood cells | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Cardiovascular Diseases - etiology | Follow-Up Studies | Humans | Middle Aged | Hematocrit | Phlebotomy | Polycythemia Vera - blood | Male | Thrombosis - epidemiology | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Polycythemia Vera - therapy | Janus Kinase 2 | Polycythemia Vera - complications | Thrombosis - etiology | Cardiovascular Diseases - mortality | Female | Hydroxyurea - therapeutic use | Aged | Control | Usage | Care and treatment | Causes of | Polycythemia vera | Diagnosis | Cardiovascular diseases | Risk factors | Clinical trials | Medical treatment | Mutation | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 07/2019, Volume 134, Issue 4, pp. 341 - 352
Life Sciences & Biomedicine | Hematology | Science & Technology | Disease Susceptibility | Humans | Middle Aged | Male | Treatment Outcome | Hematopoietic Stem Cells - metabolism | Polycythemia Vera - therapy | Evidence-Based Medicine | Polycythemia Vera - diagnosis | Polycythemia Vera - metabolism | Hematopoietic Stem Cells - cytology | Aged, 80 and over | Biomarkers | Adult | Female | Combined Modality Therapy - methods | Disease Management | Polycythemia Vera - etiology | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 22, pp. 3212 - 3220
Life Sciences & Biomedicine | Hematology | Science & Technology | Humans | Middle Aged | Janus Kinase 2 - genetics | Polycythemia Vera - blood | Male | Physician-Patient Relations | Polycythemia Vera - genetics | Polycythemia Vera - therapy | Polycythemia Vera - diagnosis | Erythropoietin - blood | DNA Mutational Analysis | Aged | Precision Medicine | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2019, Volume 134, Issue 6, pp. 525 - 533
Life Sciences & Biomedicine | Hematology | Science & Technology | Proto-Oncogene Proteins c-mdm2 - genetics | Administration, Oral | Humans | Middle Aged | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Polycythemia Vera - diagnosis | para-Aminobenzoates - administration & dosage | Antineoplastic Agents - adverse effects | para-Aminobenzoates - adverse effects | Aged, 80 and over | Biomarkers | Adult | Female | Polycythemia Vera - drug therapy | Aged | Mutation | Polycythemia Vera - etiology | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - metabolism | Index Medicus | Abridged Index Medicus | 33 | 8 | Clinical Trials and Observations
Journal Article